Fractyl Health Files 8-K
Ticker: GUTS · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1572616
| Field | Detail |
|---|---|
| Company | Fractyl Health, Inc. (GUTS) |
| Form Type | 8-K |
| Filed Date | Jan 13, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.00001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k, regulation-fd
TL;DR
Fractyl Health filed a standard 8-K, no major news.
AI Summary
Fractyl Health, Inc. filed an 8-K on January 13, 2025, reporting under Regulation FD and including financial statements and exhibits. The filing does not disclose specific financial figures or material events beyond its routine reporting nature.
Why It Matters
This 8-K filing indicates routine corporate reporting by Fractyl Health, Inc. to the SEC, without revealing new material information.
Risk Assessment
Risk Level: low — The filing is a routine 8-K report and does not contain any new material information that would impact risk.
Key Players & Entities
- FRACTYL HEALTH, INC. (company) — Registrant
- January 13, 2025 (date) — Date of Report
- 3 Van de Graaff Drive Suite 200 (address) — Principal Executive Offices
- Burlington, Massachusetts (location) — Principal Executive Offices Location
- 01803 (zip_code) — Principal Executive Offices Zip Code
FAQ
What is the primary purpose of this 8-K filing for Fractyl Health, Inc.?
The primary purpose of this 8-K filing is for Regulation FD Disclosure and to report Financial Statements and Exhibits.
On what date was this 8-K report filed?
This 8-K report was filed on January 13, 2025.
What is the exact name of the registrant as specified in its charter?
The exact name of the registrant is Fractyl Health, Inc.
Where are Fractyl Health, Inc.'s principal executive offices located?
Fractyl Health, Inc.'s principal executive offices are located at 3 Van de Graaff Drive, Suite 200, Burlington, Massachusetts, 01803.
Does this filing disclose any specific new financial results or material events?
No, this filing is a routine 8-K report and does not disclose specific new financial results or material events beyond its reporting nature.
Filing Stats: 584 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2025-01-13 07:05:17
Key Financial Figures
- $0.00001 — nge on which registered Common Stock, $0.00001 par value per share GUTS The Nasdaq
Filing Documents
- guts-20250113.htm (8-K) — 42KB
- guts-ex99_1.htm (EX-99.1) — 23KB
- 0000950170-25-004554.txt ( ) — 186KB
- guts-20250113.xsd (EX-101.SCH) — 25KB
- guts-20250113_htm.xml (XML) — 5KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On January 13, 2025, Fractyl Health, Inc. (the "Company") issued a press release announcing preliminary results demonstrating weight maintenance following GLP-1 drug discontinuation and Revita procedure in first patient of the REVEAL-1 cohort. Data from the REVEAL-1 cohort, delayed slightly due to holiday related scheduling issues, will be presented in Q1 2025. The Company also announces strong enrollment progress for the REMAIN-1 weight maintenance pivotal study. A mid-point analysis from the REMAIN-1 study is on-track and anticipated in Q2 2025. A copy of the press release in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in Item 7.01 of this Current Report (including Exhibit 99.1 attached hereto) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits The following exhibit relates to Item 7.01 and shall be deemed to be furnished, and not filed: Exhibit No. Description 99.1 Fractyl Health, Inc. Press Release dated January 13, 2025 104 Cover Page Interactive Data File (embedded within the inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Fractyl Health, Inc. Date: January 13, 2025 By: /s/ Harith Rajagopalan Harith Rajagopalan, M.D., Ph.D.